BiotechTubeBiotechTube
Home/Pipeline/AMT-162

AMT-162

Amyotrophic Lateral Sclerosis (ALS)

PreclinicalResearch

Key Facts

Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Preclinical
Status
Research
Company
uniQure

About uniQure

uniQure is a clinical-stage gene therapy company with over two decades of experience, dedicated to reimagining medicine through innovative genomic treatments. The company has built a modular AAV platform, featuring proprietary technologies like miQURE for gene silencing, and is advancing a pipeline targeting CNS and liver diseases. With a lead program, AMT-130, in late-stage development for Huntington's disease and a commercial-stage partnership for hemophilia B gene therapy, uniQure is positioned at the forefront of the gene therapy revolution.

View full company profile

Therapeutic Areas

NeurologyRare DiseasesHematology

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

DrugCompanyPhase
Utreloxastat (PTC857)PTC TherapeuticsPhase 2
SAR443820/DNL788Denali TherapeuticsPhase 2
PegcetacoplanApellis PharmaceuticalsPhase 2
RELYVRIO/ALBRIOZA (AMX0035)Amylyx PharmaceuticalsApproved/Commercial
AMX0035Amylyx PharmaceuticalsPhase 3
AMX0114Amylyx PharmaceuticalsPhase 1
Taldefgrobep alfaBiohavenPhase 2/3
AAV-UPF1MeiraGTxPreclinical
TegoprubartEledon PharmaceuticalsPhase 2
Intranasal ForalumabTiziana Life SciencesPhase 2
TDP-43 ProgramKorro BioDiscovery
COYA 302Coya TherapeuticsPhase 2